Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Oncocyte Corp. (Nasdaq: OCX) is a diagnostics technology company focused on molecular tests for organ transplantation and oncology, and its news flow reflects this dual focus. Company updates frequently describe progress toward commercializing a dd-cfDNA-based transplant rejection monitoring test kit, including clinical trial milestones, regulatory interactions, and reimbursement developments. Oncocyte also reports on the use of its proprietary assays in peer-reviewed studies and collaborations with leading transplant centers and research institutions.
Investors and clinicians following OCX news can expect regular announcements about the GraftAssure transplant portfolio, which includes the GraftAssureCore lab-developed test, the GraftAssureIQ research-use-only kit, and the planned GraftAssureDx in-vitro diagnostic kit. Recent releases have highlighted Medicare reimbursement improvements for the company’s lab-developed transplant assay, expanded coverage for specific high-risk patient groups, and adoption of GraftAssure research kits by transplant centers in the United States, Europe, and Southeast Asia.
Oncocyte’s news also covers scientific publications that use its proprietary assays to study transplant biology, such as data in Transplantation Direct examining dd-cfDNA levels and kidney allograft biopsies. In oncology, updates have discussed the role of the DetermaIO gene expression test in studies like NeoTRIP in triple negative breast cancer, as well as the DetermaCNI blood-based monitoring tool.
In addition, OCX news items report on quarterly and annual financial results, pharma services revenue from its CLIA-certified Nashville lab, capital raises, and its strategic partnership with Bio-Rad Laboratories. Corporate communications may also include participation in healthcare and diagnostics conferences and plans related to corporate renaming. For those tracking the company, the news stream provides insight into clinical, regulatory, scientific, and capital markets developments affecting Oncocyte’s transplant and oncology diagnostics programs.
Oncocyte Corporation (NYSE American: OCX) announced a favorable pricing decision from CMS for its DetermaRx™ test, which identifies high-risk early-stage lung cancer patients for chemotherapy. This decision confirms pricing within expected ranges and positions Oncocyte for immediate revenue growth. With approximately 70% of eligible patients being Medicare beneficiaries, the company anticipates increased uptake and market expansion, addressing a global market estimated at $450M - $500M. Oncocyte experienced 100% quarter-over-quarter growth in patient testing and has onboarded 55 hospitals to date.
Oncocyte (NYSE American: OCX) will present at the LD 500 investor conference on September 3, 2020, at 12:20 PM PST / 3:20 PM EST. CFO Mitch Levine and CMO Dr. Doug Ross will address a live virtual audience. This event runs from September 1-4 and aims to showcase unique companies in the capital markets amid the COVID pandemic. Oncocyte focuses on improving cancer diagnosis and treatment with its launched product, DetermaRx, a test for lung cancer recurrence, and is developing DetermaIO, which identifies immunotherapy responders.
Oncocyte Corporation (NYSE American: OCX) announced the appointment of Dr. Jennifer Levin Carter to its Board of Directors. Dr. Carter, a leader in precision medicine in oncology, previously served as VP, Head of Precision Health at Integral Health and CEO of N-of-One. Her expertise will be crucial as Oncocyte enhances its molecular diagnostics offerings, including DetermaRx™ and DetermaIO™. These tests aim to improve patient outcomes by identifying suitable cancer treatments and enhancing predictive capabilities in immunotherapy.
Oncocyte Corporation (NYSE American: OCX) will engage in 1-on-1 meetings at the Needham Virtual Cancer Diagnostics 1x1 Conference on August 18, 2020. The company specializes in molecular diagnostics aimed at enhancing cancer care. Their launched test, DetermaRx, identifies early-stage lung cancer patients at high risk for recurrence, optimizing treatment through timely adjuvant chemotherapy. Additionally, they are developing DetermaIO, which assesses patient response to immunotherapies. These innovations aim to improve patient outcomes significantly.
Oncocyte Corporation (NYSE American: OCX) reported significant advancements in its molecular diagnostics, particularly with DetermaRx™. The company secured national Medicare reimbursement starting August 2020, marking a pivotal moment for DetermaRx, which targets non-small cell lung cancer. Additionally, Oncocyte expanded its international distribution, most notably to Israel. For Q2 2020, revenues reached $143,000 with a net loss of $9.1 million, up from $5.4 million year-over-year. The firm expects annualized savings of approximately $3 million due to the discontinuation of DetermaDx™.
Oncocyte Corporation (NYSE American: OCX) will host a webinar on July 30, 2020, featuring lung cancer experts to discuss DetermaRx™, the first predictive test for early-stage lung cancer. Launched in January 2020, DetermaRx has gained Medicare coverage and is now adopted by over 40 hospitals. The test identifies patients at high risk for recurrence, potentially benefiting from adjuvant chemotherapy post-surgery. Esteemed oncologists Dr. David Gandara and Dr. Johannes Kratz will present new data demonstrating the test's clinical utility and impact on disease-free survival.
Oncocyte Corporation (OCX) announced it will release its Q2 financial and operating results for the period ending June 30, 2020, on July 29, 2020, after U.S. market close. The company will host a conference call on the same day at 4:30 PM ET to discuss these results alongside recent developments. Oncocyte specializes in molecular diagnostics with products like DetermaRx™, aimed at assessing early-stage lung cancer patients for recurrence, and DetermaIO™, which identifies patients likely to respond to immunotherapies.
Oncocyte Corporation (NYSE American: OCX) announced that Noridian has issued a final local coverage determination (LCD) for its DetermaRx™ test, establishing Medicare coverage for around 70% of eligible patients with early-stage non-small cell lung cancer (NSCLC). This marks DetermaRx™ as the first and only test in a new class of predictive tests. The estimated addressable market for the test could reach approximately $500 million globally. This development enhances patient access and validates DetermaRx™'s role in improving treatment decisions for lung cancer patients post-surgery.
Oncocyte Corporation (NYSE American: OCX) announced that its clinical validation study for DetermaDx™, a liquid biopsy test for lung nodules, did not meet its performance endpoint. Consequently, the company will cease further investment in DetermaDx and refocus on DetermaRx™ and DetermaIO™, which are currently being commercialized in clinical and biopharma markets. DetermaRx has shown promise in early-stage lung cancer management with significant market potential, while DetermaIO targets immunotherapy response prediction, addressing a need in patient selection for treatment.
Oncocyte Corporation (NYSE American: OCX) has announced significant progress as it begins generating revenue. The company has received its first diagnostic revenue for its test DetermaRx™ from multiple commercial payers and has initiated Medicare claims submissions. DetermaRx™, a predictive test for Stage I-IIA non-squamous NSCLC patients at high risk for recurrence, is now set to improve clinical outcomes and healthcare economics. The company reports consistent month-over-month increases in test volumes, marking a pivotal transition to a commercial stage operation.
FAQ
What is the current stock price of Oncocyte Corporation (OCX)?
What is the market cap of Oncocyte Corporation (OCX)?
